Belgium’s Novadip Biosciences raises €10.4 million to fund pivotal clinical trial and unlock EIB loan tranche
Novadip Biosciences, a Belgian late-stage clinical BioTech company specialising in regenerative medicine, has closed a €10.4 million (roughly $12 million) convertible financing round. The round was led by US-based New Science Ventures, with participation from a syndicate of Novadip’s existing
<p>Novadip Biosciences, a Belgian late-stage clinical BioTech company specialising in regenerative medicine, has closed a €10.4 million (roughly $12 million) convertible financing round. The round was led by US-based New Science Ventures, with participation from a syndicate of Novadip’s existing </p>